Puma Biotechnology
PBYI
68 hedge funds and large institutions have $93.8M invested in Puma Biotechnology in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 29 reducing their positions, and 12 closing their positions.
512% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $230K
9% more capital invested
Capital invested by funds: $86.1M → $93.8M (+$7.74M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.69% less ownership
Funds ownership: 59.59% → 56.9% (-2.7%)
12% less funds holding
Funds holding: 77 → 68 (-9)
52% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 29
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$358K |
| 2 |
Squarepoint
New York
|
+$231K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$159K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$94K |
| 5 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$90.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.13M |
| 2 |
EP
Eversept Partners
New York
|
-$873K |
| 3 |
Millennium Management
New York
|
-$560K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$363K |
| 5 |
Two Sigma Investments
New York
|
-$318K |
PBYI Hedge Fund Activity: Q2 2023 in Review
68 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2023, worth a combined $93.8M — up 9% from $86.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PBYI and 3 opened new positions — a net loss of 9 holders — while 29 trimmed existing stakes and 14 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $358K. The largest seller was Susquehanna International Group, cutting an estimated $1.13M.
- 68 institutional investors held Puma Biotechnology (PBYI) as of Q2 2023, down from 77 in Q1 2023.
- Funds reported $93.8M of Puma Biotechnology stock for Q2 2023, up 9% quarter-over-quarter.
- 3 funds opened new Puma Biotechnology positions in Q2 2023 and 12 closed out, a net change of -9 holders.
- The largest Puma Biotechnology buyer in Q2 2023 was GSA Capital Partners, an estimated $358K added.
- The largest Puma Biotechnology seller in Q2 2023 was Susquehanna International Group, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2023.